BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28344661)

  • 1. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.
    Kipps E; Young K; Starling N
    Ther Adv Med Oncol; 2017 Mar; 9(3):159-170. PubMed ID: 28344661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
    Woo W; Carey ET; Choi M
    Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Chiang NJ; Chang JY; Shan YS; Chen LT
    Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
    Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs.
    Milano G; Innocenti F; Minami H
    Cancer Sci; 2022 Jul; 113(7):2224-2231. PubMed ID: 35445479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
    Frampton JE
    Drugs; 2020 Jul; 80(10):1007-1018. PubMed ID: 32557396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
    Ko AH
    Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
    Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA
    J Geriatr Oncol; 2019 May; 10(3):427-435. PubMed ID: 30842038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line.
    Akhoundova Sanoyan D; Reiner CS; Papageorgiou P; Siebenhüner AR
    Case Rep Oncol; 2020; 13(1):79-84. PubMed ID: 32110224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
    Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
    Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report.
    Kim SR; Lee HJ; Kim D
    Case Rep Oncol; 2021; 14(3):1882-1888. PubMed ID: 35111024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium.
    Verbruggen L; Verheggen L; Vanhoutte G; Loly C; Lybaert W; Borbath I; Vergauwe P; Hendrickx K; Debeuckelaere C; de Haar-Holleman A; Van Laethem JL; Peeters M
    Ther Adv Med Oncol; 2023; 15():17588359231181500. PubMed ID: 37600936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer.
    Kieler M; Unseld M; Bianconi D; Prager GW
    Memo; 2017; 10(3):136-140. PubMed ID: 28989542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan.
    Yu KH; Hendifar AE; Alese OB; Draper A; Abdelrahim M; Burns E; Khan G; Cockrum P; Bhak RH; Nguyen C; DerSarkissian M; Duh MS; Bahary N
    Front Oncol; 2021; 11():678070. PubMed ID: 34336666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
    Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
    Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
    Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
    Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
    Ueno M
    Gan To Kagaku Ryoho; 2020 Jun; 47(6):955-962. PubMed ID: 32541174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
    BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
    Cinar P; Ko AH
    Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.